DURHAM, N.C. --(BUSINESS WIRE)--Jan. 4, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that Michael Amoroso , Chief Executive...
